Expand SLS Menu
SLS MENU

SLS Latest Press Releases

-- May 1, 2024 --

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level Globe Newswire 8:35 AM

-- April 29, 2024 --

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study Globe Newswire 8:45 AM

-- March 28, 2024 --

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update Globe Newswire 4:05 PM
GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib) Treating Diffuse Large B Cell Lymphoma PRNewswire 7:00 AM

-- March 26, 2024 --

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study Globe Newswire 7:35 AM

-- March 19, 2024 --

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules Globe Newswire 4:05 PM
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET Globe Newswire 8:47 AM

-- March 15, 2024 --

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules Globe Newswire 9:00 AM

-- March 8, 2024 --

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships Globe Newswire 8:00 AM

-- March 1, 2024 --

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference Globe Newswire 8:30 AM

-- February 29, 2024 --

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time Globe Newswire 8:00 AM

-- February 6, 2024 --

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget Globe Newswire 8:30 AM

-- January 25, 2024 --

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference Globe Newswire 8:45 AM

-- January 11, 2024 --

GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia PRNewswire 6:00 AM

-- January 9, 2024 --

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients Globe Newswire 8:30 AM

-- January 4, 2024 --

SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering Globe Newswire 9:01 AM

-- January 3, 2024 --

SELLAS Life Sciences Announces Proposed Public Offering Globe Newswire 8:05 PM
SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones Globe Newswire 7:30 AM

-- December 27, 2023 --

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma Globe Newswire 8:55 AM

-- December 21, 2023 --

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas Globe Newswire 8:15 AM

-- December 14, 2023 --

SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia Globe Newswire 8:30 AM

-- December 13, 2023 --

SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET Globe Newswire 8:30 AM

-- December 4, 2023 --

SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia Globe Newswire 8:47 AM